JANSSEN RISPERDAL LAUNCH SET FOR FEBRUARY; SMITHKLINE WILL COPROMOTE

Janssen plans a February launch for Risperdal following FDA's Dec. 29 approval of the dopamine/serotonin antagonist. Risperdal (risperidone) was approved for the treatment of psychotic disorders 20.5 months from the date the J&J subsidiary submitted the NDA ("The Pink Sheet" Jan. 3, p. 14). The antipsychotic received a "1P" rating, designating a new molecular entity receiving a priority review.